<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03696771</url>
  </required_header>
  <id_info>
    <org_study_id>CNJH395X2101</org_study_id>
    <nct_id>NCT03696771</nct_id>
  </id_info>
  <brief_title>Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer</brief_title>
  <official_title>A Phase I, Multicenter, Open-label Dose Finding Study of NJH395, Administered Intravenously in Patients With Non-breast HER2+ Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A first-in-human study using NJH395 in non-breast HER2-positive advanced malignancies
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has two parts. There will be a single dose of NJH395 in the first part and
      multiple doses of NJH395 in the second part. After the first part is completed, the second
      part may open.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 27, 2018</start_date>
  <completion_date type="Anticipated">August 6, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 5, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of dose limiting toxicities (DLTs)</measure>
    <time_frame>21 days</time_frame>
    <description>The time frame will expand to 42 days for the second part of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>2.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration versus time profiles for NJH395 and its catabolite</measure>
    <time_frame>126 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Cmax) for NJH395</measure>
    <time_frame>126 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameter (AUC) for NJH395</measure>
    <time_frame>126 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-NJH395 antibodies and neutralizing antibodies to trastuzumab</measure>
    <time_frame>126 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>2.5 years</time_frame>
    <description>Response assessed by RECIST v1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>Response assessed by RECIST v1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>2.5 years</time_frame>
    <description>Time from start of treatment to date of the first documented progression or death in months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>Response assessed by RECIST v1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of tumor-infiltrating lymphocytes by IHC</measure>
    <time_frame>Cycle 1 Day 5, Cycle 2 Day 1 (each cycle is 21 days), Cycle 8 Day 1 and at end of treatment (expected between months 6 and 7)</time_frame>
    <description>Change from baseline in TILs by immunohistochemistry (IHC) (such as CD8).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>NON-breast HER2+ Malignancies</condition>
  <arm_group>
    <arm_group_label>NJH395</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Includes non-breast HER2-positive advanced malignancies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NJH395</intervention_name>
    <description>Immune stimulator antibody conjugate (ISAC), consisting of a monoclonal antibody which targets HER2 conjugated to an immune-stimulatory agent</description>
    <arm_group_label>NJH395</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Patient must have known histologically or cytologically confirmed and documented
             HER2-positive solid tumor excluding patients with breast cancer

          -  Advanced/metastatic cancer with measurable disease as determined by RECIST v.1.1 who
             have progressed or are intolerant to all approved therapies known to confer clinical
             benefit.

          -  Eastern Cooperative Oncology Group (ECOG) performance status â‰¤2.

          -  Patient must have a site of disease amenable to biopsy, and be a candidate for tumor
             biopsy according to the treating institution's guidelines. Patient must be willing to
             undergo a new tumor biopsy prior to therapy, and during therapy on this study.

        Key Exclusion Criteria:

          -  History of severe hypersensitivity to any ingredient of study drug, trastuzumab or
             other monoclonal antibody.

          -  Patients previously treated with TLR 7/8 agonist.

          -  Impaired cardiac function or history of clinically significant cardiac disease

          -  Active, known or suspected autoimmune disease.

          -  Human Immunodeficiency virus (HIV) infection

          -  History of or current interstitial lung disease or pneumonitis Grade 2 or greater.

          -  Discontinued prior checkpoint inhibitor due to a checkpoint inhibitor related
             toxicity.

          -  Currently receiving medications known to cause Torsades de Pointe that cannot be
             discontinued 7 days prior to starting treatment

        Other protocol defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277 8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 4, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I, NJH395, HER2+, ISAC, TLR7</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

